Research
Hormonal
Tirzepatide treatment significantly reduced the 10-year predicted risk of developing type 2 diabetes compared with placebo in participants with obesity or overweight.
Practitioners can consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.
StrongSupportsmedium confidence
Tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight.
Why this rating
The study is a post hoc analysis of a randomized controlled trial.
Source
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the <scp>SURMOUNT</scp> ‐1 trial
Emily R. Hankosky et al. · Diabetes Obesity and Metabolism · 2023
otherCited 42×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →